Eli Lilly and Company (NYSE:LLY) Stock Price Up 1.1%

Eli Lilly and Company (NYSE:LLY - Get Free Report) rose 1.1% on Monday . The company traded as high as $925.68 and last traded at $924.78. Approximately 645,332 shares traded hands during mid-day trading, a decline of 78% from the average daily volume of 2,929,781 shares. The stock had previously closed at $914.57.

Analyst Ratings Changes

Several research analysts have commented on the company. BMO Capital Markets reaffirmed an "outperform" rating and set a $1,001.00 target price on shares of Eli Lilly and Company in a report on Wednesday, July 3rd. JPMorgan Chase & Co. increased their price objective on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the stock an "overweight" rating in a research report on Wednesday, May 1st. The Goldman Sachs Group lifted their target price on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a "neutral" rating in a research note on Thursday, April 11th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $885.00 price target on shares of Eli Lilly and Company in a research report on Monday, July 1st. Finally, Morgan Stanley reiterated an "overweight" rating and set a $1,023.00 price target on shares of Eli Lilly and Company in a report on Friday. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $816.78.

Eli Lilly and Company Stock Up 0.4 %

The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. The firm has a market capitalization of $872.47 billion, a P/E ratio of 135.20, a P/E/G ratio of 1.99 and a beta of 0.41. The stock's 50-day simple moving average is $835.30 and its 200-day simple moving average is $754.97.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The company had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. During the same period in the prior year, the company posted $1.62 earnings per share. Eli Lilly and Company's quarterly revenue was up 26.0% on a year-over-year basis. As a group, research analysts predict that Eli Lilly and Company will post 13.76 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 0.57%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company's dividend payout ratio is 76.58%.

Insider Activity

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 8,848 shares of the firm's stock in a transaction on Wednesday, July 3rd. The stock was sold at an average price of $915.31, for a total value of $8,098,662.88. Following the completion of the sale, the insider now directly owns 97,299,772 shares of the company's stock, valued at $89,059,454,309.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, EVP Johna Norton sold 7,056 shares of Eli Lilly and Company stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.38, for a total value of $5,781,545.28. Following the completion of the transaction, the executive vice president now owns 25,428 shares in the company, valued at $20,835,194.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 8,848 shares of the company's stock in a transaction that occurred on Wednesday, July 3rd. The shares were sold at an average price of $915.31, for a total transaction of $8,098,662.88. Following the sale, the insider now owns 97,299,772 shares in the company, valued at $89,059,454,309.32. The disclosure for this sale can be found here. Insiders sold 911,111 shares of company stock valued at $783,500,842 in the last three months. Company insiders own 0.13% of the company's stock.

Institutional Investors Weigh In On Eli Lilly and Company

Several institutional investors have recently made changes to their positions in the stock. Lipe & Dalton purchased a new stake in Eli Lilly and Company in the 4th quarter worth approximately $26,000. Tidemark LLC bought a new stake in Eli Lilly and Company during the fourth quarter valued at $29,000. Core Wealth Advisors Inc. grew its position in Eli Lilly and Company by 188.2% during the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company's stock worth $29,000 after buying an additional 32 shares in the last quarter. Frank Rimerman Advisors LLC bought a new position in Eli Lilly and Company in the 4th quarter worth about $37,000. Finally, St. Johns Investment Management Company LLC raised its holdings in shares of Eli Lilly and Company by 123.3% in the 4th quarter. St. Johns Investment Management Company LLC now owns 67 shares of the company's stock valued at $39,000 after acquiring an additional 37 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.